

**SUPPLEMENT II TO THE PROSPECTUS OF  
AESCAP GENETICS DATED DECEMBER 2022**

This document constitutes a supplement (the “**Supplement II**”) to the Prospectus of the Aescap Genetics dated December 2022 (the “**Prospectus**”). This Supplement II contains updated information relating to the Prospectus and shall be implemented in the updated version of the Prospectus. Until this information is implemented, this Supplement II should be read in conjunction with the Prospectus and Supplement I. Defined terms have the same meaning as ascribed to them in the Prospectus. Any Prospectus information not supplemented herein or in the prior supplements should be regarded as unchanged.

This Supplement II will be published on the website of the Fund Manager, as prescribed by section 22.4 of the Prospectus and become effective as of the date of this Supplement II.

A notice of the amendment made together with an explanation will also be published on the website of the Fund Manager, as prescribed by section 22.4 of the Prospectus.

**1: Amendment of section 13.1 (Entitlement Unit Holders to the Fund Assets) of the Prospectus**

The following paragraph will be included after the second paragraph:

*“Aescap funds managed by Privium Fund Management B.V. that invest in Aescap Genetics will invest in the AESCAP GENETICS Manager Unit Class and are therefore not charged with a management fee and performance fee.”*

Amsterdam, March 27, 2024

Privium Fund Management B.V.  
The Fund Manager